Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

The semaglutide dosing chart below shows the dosing schedule ... a different GLP-1 receptor agonist to help with weight loss. Zepbound (tirzepatide) and Saxenda (liraglutide) are two other options ...

Zepbound (tirzepatide) is a prescription injection that comes as a single-dose pen or single-dose vial. If your doctor prescribes Zepbound to you and you need to travel, there are certain things ...

Weaker than expected data from the trial was a blow to Novo's ambitions to find a more powerful competitor to Lilly's Zepbound ... After reaching the highest dose, she stopped losing weight ...

A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less than what’s been seen with competitor Eli Lilly’s Zepbound.